Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Tables)

v3.7.0.1
Commitments and Contingencies (Tables)
3 Months Ended
Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]  
Patent And Technology License Agreement, Milestone Payments [Table Text Block]
Pursuant to an amendment on October 19, 2015, the Company will pay milestone payments as follows:
 
 In thousands (except conversion rate and share information)   
 
Phase
 
Amount
 
 
 
 
 
Commencement of Phase II Study for a licensed product
 
$
200
 
Commencement of Phase III Study for a licensed product
 
$
250
 
Filing of a New Drug Application for a licensed product
 
$
400
 
Receipt of market approval for a licensed product
 
$
500